- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03186014
A Fully Covered Irradiation Stent for the Palliation of Malignant Dysphagia
June 9, 2017 updated by: Gao-jun Teng, Zhongda Hospital
A Novel Fully Covered Segmented Irradiation Stent Loaded With 125I Seeds for the Palliation of Malignant Dysphagia:a Prospective Pilot Study
Dysphagia is the major symptom of patients with malignant esophageal stricture caused predominantly by advanced esophageal cancer.
Stent placement is the most commonly used strategies for relieving the dysphagia and a novel irradiation stent loaded with 125I seeds has recently been developed.
A multicentre randomized clinical trial demonstrated this irradiation stent can relieve the dysphagia rapidly and prolong the survival of patients with advanced esophageal cancer, but the total stent stenosis rate cannot be ruduced.
A novel fully covered segmented retrievable irradiation stent was developed in our institute.
The purpose of this study is to evaluate the safety and clinical efficacy of this newly developed irradiation stent in patients with unresectable malignant dysphagia.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Esophageal cancer is the eighth most common cancer and the sixth leading cause of cancer related mortality worldwide.
Most patients have lost chance of surgical resection when they are initially diagnosed, because of late stage cancer or metastasis.
Dysphagia is the major symptom of patients with advanced esophageal cancer.
The two most commonly used strategies for relieving the dysphagia are stent placement and intraluminal brachytherapy.
Stent placement provides a fast improvement of dysphagia, while intraluminal brachytherapy provides a more durable effect on dysphagia.
To combine the advantages of the immediate relief of esophageal dysphagia with stent placement and long-term benefit with brachytherapy, a novel irradiation stent loaded with 125I seeds has been developed in the authors' institute.
Recently, a multicentre randomized clinical trial demonstrated this novel irradiation stent can relieve the dysphagia rapidly and prolong the survival of patients with advanced esophageal cancer.
However, this irradiation stent only provides a slightly longer relief of dysphagia and cannot reduce the total stent stenosis rate, because partly covered stent with uncoated flanges on both ends for anchoring the stent are used.
In the past few years, fully covered retrievable stents which allow less tissue overgrowth have been used in patients with longer life expectancy, especially if they are receiving additional palliative therapy like brachytherapy.
In order to provide a further longer relief of dysphagia and prevent stent migration caused by tumor regresses with brachytherapy, a fully covered segmented retrievable irradiation stent has been developed.
The aim of the current study is to evaluate the clinical efficacy, particularly focus on stent stenosis and stent migration, and safety of this newly developed irradiation stent in patients with unresectable malignant dysphagia.
Study Type
Interventional
Enrollment (Anticipated)
38
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chao Wang, Ph.D
- Phone Number: +86 151 9585 3100
- Email: wangchaoseu@126.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Recruiting
- Zhongda Hospital,Southeast University
-
Contact:
- Chao Wang
- Email: wangchaoseu@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Endoscopically and histologically confirmed malignant obstruction of the esophagus or the gastroesophageal junction
- Progressive dysphagia with a dysphagia score of 2-4
- Unresectable tumours due to extensive lesions, metastases, or poor medical condition
- Patients with clear consciousness, cooperation
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3
- Informed consent: authorization and signature
Exclusion Criteria:
- The superior border of the lesion extending beyond the level of the seventh cervical vertebrae
- Previous treatment with a stent or surgical resection for the same condition
- Ulcerative esophageal cancer
- Esophageal fistula
- Severe hepatic inadequacy or renal inadequacy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fully covered irradiation stent
A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
|
A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrent dysphagia
Time Frame: Participants will be followed till die or lost to follow-up, an expected average of 6 months.
|
The rate of occurrence of tissue ingrowth or overgrowth, stent migration, and food obstruction.
|
Participants will be followed till die or lost to follow-up, an expected average of 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dysphagia score
Time Frame: Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
Investigated with the Ogilvie score: 0 for nil, 1 for normal diet avoiding certain foods such as raw apple and steak, 2 for semi-solid diet, 3 for fluids only, and 4 for complete dysphagia, even for liquids.
|
Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
ECOG performance status
Time Frame: Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
Utilizing ECOG performance status score to assess the functional status.
|
Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
EORTC QLQ-C30
Time Frame: Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
Utilizing EORTC QLQ-C30 to assess the health-related quility of life.
|
Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
EORTC QLQ-OG25
Time Frame: Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
Utilizing EORTC QLQ-OG25 to assess the health-related quility of life in patients with cancer of the oesophagus and the oesophago-gastric junction.
|
Baseline, post-op 7 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months
|
Technical success
Time Frame: During operation
|
The rate of adequate placement of the stent in the target position and good passage of contrast medium through the stent into the stomach.
|
During operation
|
Clinical success
Time Frame: 3 days after stent placement
|
The rate of relief of dysphagia with a decrease of at least one point in the dysphagia score.
|
3 days after stent placement
|
Overall survival
Time Frame: Participants will be followed till die or lost to follow-up, an expected average of 6 months.
|
Time from initial stenting to the day when the patients died or lost to follow-up.
|
Participants will be followed till die or lost to follow-up, an expected average of 6 months.
|
Stent patency
Time Frame: Participants will be followed till die or lost to follow-up, an expected average of 6 months.
|
Time from initial stenting to the day when recurrent dysphagia occured or patients died.
|
Participants will be followed till die or lost to follow-up, an expected average of 6 months.
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: Participants will be followed till die or lost to follow-up, an expected average of 6 months.
|
Adverse events including hemorrhage, perforation, fistula, severe chest pain, and pneumonia.
|
Participants will be followed till die or lost to follow-up, an expected average of 6 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 1, 2017
Primary Completion (Anticipated)
October 1, 2018
Study Completion (Anticipated)
October 1, 2018
Study Registration Dates
First Submitted
June 7, 2017
First Submitted That Met QC Criteria
June 9, 2017
First Posted (Actual)
June 14, 2017
Study Record Updates
Last Update Posted (Actual)
June 14, 2017
Last Update Submitted That Met QC Criteria
June 9, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017ZDSYLL027
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Dysphagia
-
McGill University Health Centre/Research Institute...Terminated
-
Morinaga Milk Industry Co., LTDHospital de MataróRecruitingDysphagia | Swallowing Disorder | Dysphagia, Oral Phase | Dysphagia, Esophageal | Dysphagia, OropharyngealSpain
-
All India Institute of Medical Sciences, New DelhiRecruitingOropharyngeal Dysphagia | Dysphagia, Late Effect of Stroke | Transfer Dysphagia | Cricopharyngeus Muscle DysfunctionIndia
-
National Taiwan University HospitalRecruitingDysphagia, Swallowing Function, Diet Modification, Dysphagia Diet, Diet StandardizationTaiwan
-
University of Southern CaliforniaRecruitingDysphagia | Pharyngeal Dysphagia | Oral Pharyngeal DysphagiaUnited States
-
Peter Belafsky, MDTerminatedDysphagia | Oropharyngeal Dysphagia (OPD)United States
-
Atlantic Health SystemRecruitingPost Extubation DysphagiaUnited States
-
University of California, DavisCalifornia Institute for Regenerative Medicine (CIRM); Cook MyoSiteRecruitingOropharyngeal DysphagiaUnited States
-
University of British ColumbiaB.C. Rehabilitation FoundationCompletedThin Liquid DysphagiaCanada
-
Assiut UniversityNot yet recruitingPediatric Post Extubation Dysphagia
Clinical Trials on Fully covered irradiation stent
-
Foundation for Liver ResearchCompletedEsophageal Cancer | Esophageal StenosisNetherlands
-
Cook Group IncorporatedCompletedEsophageal Neoplasms | Stents | Esophageal Perforation | Esophageal Fistula | Esophageal StenosisUnited States
-
AdventHealthCompletedPancreatic Collection | Infected Pancreatic Necrosis | Acute Pancreatic Fluid Collection | Pancreatic and Peripancreatic Necrosis | Symptomatic Pancreatic NecrosisUnited States
-
Indiana UniversityWithdrawn
-
Cook Group IncorporatedCompletedCarcinomas/NeoplasmsCanada, United States, France, Netherlands
-
Radboud University Medical CenterErasmus Medical CenterTerminatedOesophageal Cancer | Esophageal Stent StenosisNetherlands
-
Seoul National University HospitalRecruitingHepatocellular Carcinoma | Malignant Biliary ObstructionKorea, Republic of
-
Merit Medical Systems, Inc.University of Colorado, Denver; Mayo Clinic; University of Florida; Medical College... and other collaboratorsCompletedMalignant Esophageal StricturesUnited States
-
Boston Scientific CorporationCompletedCholestasis, ExtrahepaticUnited States
-
Boston Scientific CorporationCompletedPancreatic CancerUnited States, Korea, Republic of, Belgium, Italy, Japan, Canada